Matches in SemOpenAlex for { <https://semopenalex.org/work/W2360012963> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2360012963 endingPage "8" @default.
- W2360012963 startingPage "84" @default.
- W2360012963 abstract "To test the MIC of ofloxacin and levofloxacin (MIC(F) and MIC(V)) in 101 strains of Mycobacterium tuberculosis (M. tb) isolated from patients with active tuberculosis and to analyze the relation between MIC and past history of fluoroquinolones (FQs) administration. And according to the analysis of the therapeutic effect of the regimen including FQs, we want to define the resistant breakpoints of OFLX and LVFX clinically.All isolates from sputa or pus obtained from in-patients in our hospital from Jan 1999 to Sept 2000 were tested for MIC and susceptibility. 47 patients with pulmonary tuberculosis received regimens including FQs were observed consecutively. Chi-square test was applied for the statistical analysis.(1) The MIC(V) of 96% clinical isolates tested were 2 times lower than MIC(F). (2) The MIC(F) < 8 microg/ml and MIC(V) < 4 microg/ml were found among 91% and 92% patients without previous FQs administration, while only the MIC(F) > or = 8 microg/ml and MIC(V) > or = 4 microg/ml were found among 54% and 57% for the patients with FQs administration history. (3) If MIC(F) > or = 8 microg/ml and MIC(V) > or = 4 microg/ml were defined as the clinical resistant breakpoints, in susceptible group, the sputum negative conversion rates were 54%, 75% and 82% respectively after receiving the regimens including FQs in 3, 6, and 12 months, while 16%, 32%, and 42% respectively in resistant group, (P < 0.01). Also, there were significant differences between these two groups for chest X-ray improvements after 12 months' treatment, (P < 0.01). There were significant differences for sputum conversion rates and chest X-ray improvement between MIC(V) < 4 microg/ml and MIC(V) > or = 4 microg/ml groups (P < 0.01).According to the evaluation for the therapeutic effects of regimens including FQs, it is suggested that MIC(F) > or = 8 microg/ml and MIC(V) > or = 4 microg/ml be defined as resistant breakpoints clinically. The emergence of resistance to FQs in patients with tuberculosis can influence the therapeutic effects." @default.
- W2360012963 created "2016-06-24" @default.
- W2360012963 creator A5013845234 @default.
- W2360012963 creator A5022255388 @default.
- W2360012963 creator A5023786283 @default.
- W2360012963 creator A5029418945 @default.
- W2360012963 creator A5042609974 @default.
- W2360012963 creator A5069010179 @default.
- W2360012963 date "2004-02-01" @default.
- W2360012963 modified "2023-10-18" @default.
- W2360012963 title "[A preliminary study on the definition of resistant breakpoints of ofloxacin and levofloxacin for Mycobacterium tuberculosis]." @default.
- W2360012963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14990180" @default.
- W2360012963 hasPublicationYear "2004" @default.
- W2360012963 type Work @default.
- W2360012963 sameAs 2360012963 @default.
- W2360012963 citedByCount "0" @default.
- W2360012963 crossrefType "journal-article" @default.
- W2360012963 hasAuthorship W2360012963A5013845234 @default.
- W2360012963 hasAuthorship W2360012963A5022255388 @default.
- W2360012963 hasAuthorship W2360012963A5023786283 @default.
- W2360012963 hasAuthorship W2360012963A5029418945 @default.
- W2360012963 hasAuthorship W2360012963A5042609974 @default.
- W2360012963 hasAuthorship W2360012963A5069010179 @default.
- W2360012963 hasConcept C126322002 @default.
- W2360012963 hasConcept C142724271 @default.
- W2360012963 hasConcept C176947019 @default.
- W2360012963 hasConcept C2776301714 @default.
- W2360012963 hasConcept C2777975735 @default.
- W2360012963 hasConcept C2778049240 @default.
- W2360012963 hasConcept C2778512257 @default.
- W2360012963 hasConcept C2781069245 @default.
- W2360012963 hasConcept C2781276175 @default.
- W2360012963 hasConcept C3019249092 @default.
- W2360012963 hasConcept C501593827 @default.
- W2360012963 hasConcept C71924100 @default.
- W2360012963 hasConcept C86803240 @default.
- W2360012963 hasConcept C89423630 @default.
- W2360012963 hasConcept C90924648 @default.
- W2360012963 hasConceptScore W2360012963C126322002 @default.
- W2360012963 hasConceptScore W2360012963C142724271 @default.
- W2360012963 hasConceptScore W2360012963C176947019 @default.
- W2360012963 hasConceptScore W2360012963C2776301714 @default.
- W2360012963 hasConceptScore W2360012963C2777975735 @default.
- W2360012963 hasConceptScore W2360012963C2778049240 @default.
- W2360012963 hasConceptScore W2360012963C2778512257 @default.
- W2360012963 hasConceptScore W2360012963C2781069245 @default.
- W2360012963 hasConceptScore W2360012963C2781276175 @default.
- W2360012963 hasConceptScore W2360012963C3019249092 @default.
- W2360012963 hasConceptScore W2360012963C501593827 @default.
- W2360012963 hasConceptScore W2360012963C71924100 @default.
- W2360012963 hasConceptScore W2360012963C86803240 @default.
- W2360012963 hasConceptScore W2360012963C89423630 @default.
- W2360012963 hasConceptScore W2360012963C90924648 @default.
- W2360012963 hasIssue "2" @default.
- W2360012963 hasLocation W23600129631 @default.
- W2360012963 hasOpenAccess W2360012963 @default.
- W2360012963 hasPrimaryLocation W23600129631 @default.
- W2360012963 hasRelatedWork W1482866462 @default.
- W2360012963 hasRelatedWork W1984653500 @default.
- W2360012963 hasRelatedWork W2095103140 @default.
- W2360012963 hasRelatedWork W2100856600 @default.
- W2360012963 hasRelatedWork W2111538166 @default.
- W2360012963 hasRelatedWork W2131422994 @default.
- W2360012963 hasRelatedWork W2153869172 @default.
- W2360012963 hasRelatedWork W2170382400 @default.
- W2360012963 hasRelatedWork W2349811424 @default.
- W2360012963 hasRelatedWork W2412660437 @default.
- W2360012963 hasVolume "27" @default.
- W2360012963 isParatext "false" @default.
- W2360012963 isRetracted "false" @default.
- W2360012963 magId "2360012963" @default.
- W2360012963 workType "article" @default.